adding CTC into the existing NHS Bowel Cancer Screening Programme as part of a preventive screening strategy could be less costly to the NHS over the longer term when used to triage FOBT-positive patients to appropriate follow-up. Increased demand for radiology services may be compensated for by reduced demand in endoscopy units.

IntroductionThe estimation of utility values for the economic evaluation of therapies for wet age-related macular degeneration (AMD) is a particular challenge. Previous economic models in wet AMD have been criticized for failing to capture the bilateral nature of wet AMD by modelling visual acuity (VA) and utility values associated with the better-seeing eye only.MethodsHere we present a de novo regression analysis using generalized estimating equations (GEE) applied to a previous dataset of time trade-off (TTO)-derived utility values from a sample of the UK population that wore contact lenses to simulate visual deterioration in wet AMD. This analysis allows utility values to be estimated as a function of VA in both the better-seeing eye (BSE) and worse-seeing eye (WSE).ResultsVAs in both the BSE and WSE were found to be statistically significant (p < 0.05) when regressed separately. When included without an interaction term, only the coefficient for VA in the BSE was significant (p = 0.04), but when an interaction term between VA in the BSE and WSE was included, only the constant term (mean TTO utility value) was significant, potentially a result of the collinearity between the VA of the two eyes. The lack of both formal model fit statistics from the GEE approach and theoretical knowledge to support the superiority of one model over another make it difficult to select the best model.ConclusionLimitations of this analysis arise from the potential influence of collinearity between the VA of both eyes, and the use of contact lenses to reflect VA states to obtain the original dataset. Whilst further research is required to elicit more accurate utility values for wet AMD, this novel regression analysis provides a possible source of utility values to allow future economic models to capture the quality of life impact of changes in VA in both eyes.FundingNovartis Pharmaceuticals UK Limited.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-017-0620-x) contains supplementary material, which is available to authorized users.

Objective: Indirectly compare the efficacy and safety of ertugliflozin (ertu) from the VERTIS MET and FACTORIAL trials to other SGLT2i as an add-on to MET. Methods: Pubmed, EMBASE and Cochrane databases were searched through to end 2016 for RCTs of 24-26 weeks duration in T2DM patients with uncontrolled A1C on MET. Comparators to ertu 5mg and 15mg were low and high doses of SGLT2i licensed in Europe and USA: canagliflozin (cana), dapagliflozin (dapa) and empagliflozin (empa). Included outcomes vs. placebo at 24-26 weeks were change in A1C, weight, systolic blood pressure (SBP), A1C &lt;7% and safety outcomes (urinary tract infections [UTIs], genital mycotic infections [GMIs], hypoglycemic events and patients with ≥1 adverse event [AE]). Evidence synthesis used both fixed effect (FE) and random effects (RE) Bayesian NMA, with model selection informed by guidelines. Credible intervals (CrI), analogous to 95% confidence intervals, were used to determine significance. Results: The NMA included 7 RCTs. Ertu was significantly more effective in reducing A1C than dapa doses (ertu 5mg vs. dapa 5mg mean difference (MD): -0.22%, CrI -0.42, -0.02; ertu 15mg vs. dapa 10mg MD:-0.26%, CrI -0.46, -0.06) and ertu 15mg was superior to empa 25mg (MD: -0.23%, CrI -0.44, -0.03). There were no further significant differences between ertu and other SGLT2i for change in A1C, SBP, weight, A1C &lt;7%, UTIs or ≥1 AEs. Limited number of hypoglycemic and GMI events in placebo comparators resulted in non-convergence for these networks. The impact of heterogeneity was tested, but potential confounding due to differences in factors such as study design and patient population may remain. Conclusions: Although reliant upon indirect comparison rather than head to head RCTs, ertu 5 and 15mg were superior to dapa 5 and 10mg, respectively, and ertu 15mg was superior to empa 25mg. Across remaining outcomes, both ertu doses added to MET were comparable to other SGLT2i. Disclosure A. McNeill: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. G.M. Davies: Employee; Self; Merck & Co., Inc. E. Kruger: Employee; Self; QuintilesIMS. T. Reason: None. F. Ejzykowicz: Employee; Self; Merck Sharp & Dohme Corp. H. Hannachi: Employee; Self; Merck & Co., Inc. N.B. Cater: Employee; Self; Peter Sheehan Diabetes Care Foundation, Inc. E. McLeod: Employee; Self; Pfizer Inc..

The mean basal insulin daily dose increased by 2.04 units (SD= 16.71) compared to pre switch insulin dose. The dose increase was driven by an increased dose in the first 90 days after index date. Hereafter a return to the baseline insulin dose level was observed. There was no significant weight change and of as for health expenditure there was a small increase in visits to diabetes specialist and use of self-blood glucose measurement sticks. ConClusions: In a real life setting, switch from another insulin to IDeg significantly improved glycemic control in Type 2 DM patients with no significant weight gain and only a minor initial dose increase after IDeg initiation.